These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 4349136)

  • 21. Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen.
    Lithell H; Boberg J; Hedstrand H; Hellsing K; Ljunghall S; Vessby B
    Eur J Clin Pharmacol; 1977 Aug; 12(1):51-7. PubMed ID: 332503
    [No Abstract]   [Full Text] [Related]  

  • 22. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
    Gustafson A
    Postgrad Med J; 1975; 51(8):suppl 66-71. PubMed ID: 215983
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term treatment of hyperlipidemic patients with clofibrate.
    Berkowitz D
    JAMA; 1971 Nov; 218(7):1002-5. PubMed ID: 5000568
    [No Abstract]   [Full Text] [Related]  

  • 24. Familial lipoatrophic diabetes with dominant transmission. A new syndrome.
    Dunnigan MG; Cochrane MA; Kelly A; Scott JW
    Q J Med; 1974 Jan; 43(169):33-48. PubMed ID: 4362786
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
    Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
    Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
    Bucalossi A; Buzzelli G; D'Alessandro A
    Clin Ter; 1979 Apr; 89(2):127-49. PubMed ID: 226307
    [No Abstract]   [Full Text] [Related]  

  • 27. Classifications of the hyperlipidemias.
    Havel RJ
    Annu Rev Med; 1977; 28():195-209. PubMed ID: 193431
    [No Abstract]   [Full Text] [Related]  

  • 28. A physician's guide to hyperlipidemia.
    Fredrickson DS
    Mod Concepts Cardiovasc Dis; 1972 Jul; 41(7):31-6. PubMed ID: 4343098
    [No Abstract]   [Full Text] [Related]  

  • 29. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
    Nikkilä EA; Ylikahri R; Huttunen JK
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapy of hyperlipemia and hyperuricemia with a combination of clofibrate and an extractive mucopolysaccharide complex].
    Loizzi P; Terlizzi N
    Reumatismo; 1975; 27(1):157-62. PubMed ID: 184507
    [No Abstract]   [Full Text] [Related]  

  • 31. [Comparative studies on the reduction of lipids using clofibric acid and clofibrate in hyperlipoproteinemias].
    Schwartzkopff W; Hoffmann H; Kästner W
    Med Welt; 1975 Dec; 26(51):2308-15. PubMed ID: 177837
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
    Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R
    MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of hyperlipidemia.
    Levy RI; Morganroth J; Rifkind BM
    N Engl J Med; 1974 Jun; 290(23):1295-301. PubMed ID: 4363888
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma endogenous triglyceride transport in hypertriglyceridaemia and effect of a hypolipidaemic drug (SU-13437).
    Nikkilä EA; Kekki M
    Eur J Clin Invest; 1972 Jun; 2(4):231-8. PubMed ID: 4559814
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate].
    Gaertner U; Johannes KJ
    MMW Munch Med Wochenschr; 1976 Sep; 118(36):1127-30. PubMed ID: 184377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Differential diagnosis and differential treatment of carbohydrate tolerance disorders in patients with hyperlipoproteinemia. Behavior of plasma lipids, glucose tolerance, and plasma insulin after glucose load during treatment with clofibrate].
    Bruns W; Rjasanowski I; Wulfert P; Michael R; Knospe S; Hildmann W
    Endokrinologie; 1974 Nov; 64(1):2-12. PubMed ID: 4466653
    [No Abstract]   [Full Text] [Related]  

  • 37. Polyneuropathy associated with hyperlipemia.
    Bechar M; Kott E; Bornstein B
    Confin Neurol; 1969; 31(5):281-8. PubMed ID: 5383223
    [No Abstract]   [Full Text] [Related]  

  • 38. Carbohydrate metabolism in various types of hyperlipoproteinaemia.
    Romics L; Stützel M; Balázsi I; Varsányi-Nagy M
    Acta Med Acad Sci Hung; 1976; 33(3):225-32. PubMed ID: 1031550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoreactive insulin, glucose tolerance, and carbohydrate inducibility in types II, 3, IV, and V hyperlipoproteinemia.
    Glueck CJ; Levy RI; Fredrickson DS
    Diabetes; 1969 Nov; 18(11):739-47. PubMed ID: 5348517
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of vitamin E on serum cholesterol and triglycerides in hyperlipidemic patients treated with diet and clofibrate.
    Leonhardt ET
    Am J Clin Nutr; 1978 Jan; 31(1):100-5. PubMed ID: 202160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.